Heart Podcast Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases
Oct 13, 2021
Dr Guarav Gulsin from the University of British Columbia discusses the benefits of SGLT2 inhibitors in cardiovascular diseases, highlighting reductions in heart failure risk and mortality rates. The podcast explores renal benefits, dosages, ongoing trials, and potential applications in patients with diabetes and beyond.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Cardiovascular Benefits of SGLT2 Inhibitors
02:29 • 11min
Exploring the Renal Benefits of Sodium Glucose Cotransporter 2 Inhibitors
13:22 • 2min
Considerations and Management of SGLT2 Inhibitors
15:37 • 6min
Exploring Ongoing Trials and Unanswered Questions in SGLT2 Inhibitors for Cardiovascular Diseases
21:23 • 2min